AXLA

In a report released on November 1, Thomas Smith from SVB Securities maintained a Buy rating on Axcella Health (AXLA - Research Report), with a price target of $6.00. The company's shares closed yesterday at $0.90.According to TipRanks, Smith is an analyst with an average return of -5.1% and a 38.87% success rate. Smith covers the Healthcare sector, focusing on stocks such as Keros Therapeutics, MannKind, and Eledon Pharmaceuticals.Axcella Health has an analyst consensus of Strong Buy, with a price target consensus of $6.80, implying a 655.56% upside from current levels.
https://www.tipranks.com/news/blurbs/svb-securities-keeps-their-buy-rating-on-axcella-health-axla-2?utm_source=advfn.com&utm_medium=referral